Chemokine Therapeutics Corp., a biotechnology company, announced that the US Patent and Trademark Office has issued US Patent 7,091,310 B2 relating to chemokine analogs for the treatment of human disease.

The patent covers chemokine analogs (peptide agonists and antagonists of chemokines) that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and disorders, including autoimmune diseases, acute chronic inflammation, cancer, cardiovascular disease, infectious disease and inflammatory disorders such as rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, atherosclerosis, psoriasis, rhinitis, autoimmunity and organ transplant rejection.

Dr Hassan Salari, president and CEO of Chemokine Therapeutics, stated, "This new patent grant reinforces our overriding strategy to broaden the proprietary scope of our drug development platform while helping to further solidify our intellectual property position."